Y
Yukito Ichinose
Researcher at Kyushu University
Publications - 313
Citations - 17698
Yukito Ichinose is an academic researcher from Kyushu University. The author has contributed to research in topics: Lung cancer & Survival rate. The author has an hindex of 49, co-authored 309 publications receiving 16490 citations. Previous affiliations of Yukito Ichinose include Kindai University & Memorial Hospital of South Bend.
Papers
More filters
Journal ArticleDOI
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Tony Mok,Yi-Long Wu,Sumitra Thongprasert,Chih-Hsin Yang,Da Tong Chu,Nagahiro Saijo,Patrapim Sunpaweravong,Baohui Han,Benjamin Margono,Benjamin Margono,Yukito Ichinose,Yutaka Nishiwaki,Yuichiro Ohe,Jin Ji Yang,Busyamas Chewaskulyong,Haiyi Jiang,Emma Duffield,Claire Watkins,Alison Armour,Masahiro Fukuoka +19 more
TL;DR: Gefit inib is superior to carboplatin-paclitaxel as an initial treatment for pulmonary adenocarcinoma among nonsmokers or former light smokers in East Asia and the presence in the tumor of a mutation of the EGFR gene is a strong predictor of a better outcome with gefitinib.
Journal ArticleDOI
A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung
Harubumi Kato,Yukito Ichinose,Morio Ohta,Enjo Hata,Noriaki Tsubota,Hirohito Tada,Yoh Watanabe,Hiromi Wada,Masahiro Tsuboi,Nobuyuki Hamajima,Mitsuo Ohta +10 more
TL;DR: In this article, a combination of uracil and tegafur (often referred to as UFT) taken orally was shown to prolong survival in non-small-cell lung cancer.
Journal ArticleDOI
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Shoji Kudoh,Harubumi Kato,Yutaka Nishiwaki,Masahiro Fukuoka,Nakata K,Yukito Ichinose,Masahiro Tsuboi,Soichiro Yokota,Kazuhiko Nakagawa,Moritaka Suga,Haiyi Jiang,Yohji Itoh,Alison Armour,Claire Watkins,Tim Higenbottam,Fredrik Nyberg +15 more
TL;DR: ILD was relatively common in these Japanese patients with NSCLC during therapy with gefitinib or chemotherapy, being higher in the older, smoking patient with preexisting ILD or poor performance status, mainly in the first 4 weeks.
Journal ArticleDOI
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Roy S. Herbst,Yan Sun,Wilfried Eberhardt,Paul Germonpré,Nagahiro Saijo,Caicun Zhou,Jie Wang,Longyun Li,Fairooz F. Kabbinavar,Yukito Ichinose,Shukui Qin,Li Zhang,Bonne Biesma,John V. Heymach,Peter Langmuir,Sarah J. Kennedy,Hiroomi Tada,Bruce E. Johnson +17 more
TL;DR: The addition of vandetanib to docetaxel provides a significant improvement in PFS in patients with advanced NSCLC after progression following first-line therapy, supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC).
Journal ArticleDOI
Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer
Riichiroh Maruyama,Yutaka Nishiwaki,Tomohide Tamura,Nobuyuki Yamamoto,Masahiro Tsuboi,Kazuhiko Nakagawa,Tetsu Shinkai,Shunichi Negoro,Fumio Imamura,Kenji Eguchi,Koji Takeda,Akira Inoue,Keisuke Tomii,Masao Harada,Noriyuki Masuda,Haiyi Jiang,Yohji Itoh,Yukito Ichinose,Nagahiro Saijo,Masahiro Fukuoka +19 more
TL;DR: Gefitinib significantly improved objective response rate and quality of life versus docetaxel; progression-free survival, disease control rates, and symptom improvement were similar for the two treatments.